Mylan’s Acquisition of Global Marketing Rights to Once-Monthly Glatiramer Acetate Product through an Investment in and Partnership with Mapi Pharma
April 10, 2018
On April 10, 2018, Mylan N.V. (“Mylan”), a global pharmaceutical company, and Mapi Pharma Ltd. (“Mapi Pharma”), a fully integrated, clinical late stage biopharmaceutical company, announced that they will partner on the development and commercialization of GA Depot, a proposed once-monthly injection for the treatment of patients with relapsing-remitting multiple sclerosis. Mylan is acquiring global marketing rights to the product. Cravath is representing Mylan in connection with the transaction.
The Cravath team is led by partners Aaron M. Gruber and Mark I. Greene and includes associate Alex L. Winkelman on M&A matters; partner David J. Kappos and associate Sean M. Gholz on intellectual property matters; and associate Damien J. Rose on tax matters.
Related Practices & Industries
People
- Photo
-
-
J.D., 2007, Stanford Law SchoolOrder of the Coif
-
M.Phil., 2004, University of CambridgeGates Cambridge Scholar
-
B.S., 2003, Yale Collegesumma cum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 1993, University of Pennsylvania Law School
-
B.A., 1989, Cornell University
- New York
Education
Admitted In
- Photo
-
-
J.D., 1990, University of California, Berkeley, School of Law
-
B.S., 1983, University of California, Davissumma cum laude
- New York
- California
- District of Columbia
Education
Admitted In
Related News & Insights
Deals & Cases
April 29, 2024
Mylan’s Appellate Win Affirming Summary Judgment in Securities Class Action
On Monday, April 15, 2024, the U.S. Court of Appeals for the Second Circuit affirmed the U.S. District Court for the Southern District of New York’s granting of summary judgment in favor of Cravath client Mylan in a securities class action related to Mylan’s marketing, pricing and classification of EpiPen as well as alleged conduct concerning generic drug price fixing and market allocation.
